Hepatitis B (bodily fluids, 90 day incubation period)
π¦ Hepatitis B β Overview for NP Students
𧬠What Is It?
Hepatitis B virus (HBV) is a DNA virus that infects the liver, causing inflammation. It can lead to acute or chronichepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
Part of the Hepadnaviridae family
Spread through blood and body fluids
π Transmission Routes (CHILD mnemonic)
Mode | Examples |
|---|---|
Childbirth | Perinatal (mother to child) β especially in endemic areas |
High-risk sex | Unprotected sex, MSM, multiple partners |
Iv drug use | Needle sharing, unsafe injections |
Living with infected person | Household contact (less common in adults) |
Dialysis / healthcare | Occupational exposure, needlesticks |
π Epidemiology
~257 million people live with chronic HBV worldwide
In the U.S., most new cases occur in unvaccinated adults
Perinatal transmission leads to 90% risk of chronic infection (vs ~5% in adults)
π§ͺ HBV Serology Simplified
Marker | What it Means |
|---|---|
HBsAg (Surface Antigen) | Active infection (acute or chronic) |
Anti-HBs (Surface Antibody) | Immunity (past infection or vaccination) |
Anti-HBc (Core Antibody) | Past or current infection (not from vaccine) |
IgM anti-HBc | Acute infection |
HBeAg | High infectivity |
Anti-HBe | Lower infectivity |
HBV DNA | Viral load (used to monitor replication and treatment response) |
π§ Clinical Phases
Acute Hepatitis B
May be asymptomatic or cause fatigue, jaundice, nausea, RUQ pain
Elevated LFTs, positive HBsAg, IgM anti-HBc
Usually resolves in adults
Chronic Hepatitis B (HBsAg > 6 months)
Persistent infection with risk of cirrhosis and HCC
May be immune tolerant, inactive carrier, or active hepatitis
π§ββ NP Role in Screening & Diagnosis
π Who to Screen?
People born in endemic regions (e.g. Asia, Africa)
Pregnant women (universal)
People who inject drugs
MSM
HIV or HCV-positive patients
Household contacts of HBV-positive individuals
π Labs to Order:
HBsAg, anti-HBs, anti-HBc (initial screen)
If positive: check HBeAg, anti-HBe, HBV DNA, LFTs
π Management
π§Ύ Acute HBV:
Supportive care
Monitor LFTs and symptoms
Rarely needs antiviral therapy unless fulminant hepatitis
π Chronic HBV:
Refer to GI or hepatology
Consider antiviral therapy (e.g., tenofovir, entecavir) if:
Elevated ALT
High HBV DNA
Evidence of liver damage (biopsy/fibroscan)
π‘ Monitor for:
Cirrhosis (LFTs, platelets, imaging)
Hepatocellular carcinoma: Ultrasound every 6 months if cirrhotic or high-risk
π Prevention
β Vaccine:
3-dose series (0, 1, 6 months) OR newer 2-dose option (e.g., Heplisav-B)
Universal newborn vaccination
Pre-exposure vaccination for:
Healthcare workers
High-risk adults (e.g., IV drug users, MSM)
πΆ Birth Protocol:
If mom is HBsAg-positive:
Give HBIG + HBV vaccine to infant within 12 hours of birth
π£ Patient Education
HBV is not spread through casual contact (hugging, kissing, coughing)
Use condoms and avoid sharing needles/razors
Do not donate blood
Alcohol avoidance is critical to prevent liver damage
Importance of regular follow-up to monitor liver health
Vaccinate household and sexual contacts
β Key Clinical Pearls
HBsAg + Anti-HBc IgM = acute infection
HBsAg > 6 months = chronic infection
Anti-HBs only = vaccinated
Anti-HBs + Anti-HBc = recovered from infection
All pregnant women should be screened at first prenatal visit